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Introduction
Bladder cancer is the fifth most common malignancy in the Western society; more than 70,000 new cases of bladder cancer are diagnosed every year in the United States (1) . About 70% of patients present with non-muscle invasive bladder tumors, and the remaining 30% present with high-grade invasive tumors at initial diagnosis. Low-grade non-muscle invasive bladder tumors can be treated by transurethral resection with an excellent patient prognosis.
But high-grade non-muscle invasive bladder cancer, including carcinoma in situ (CIS), tends to invade the muscle layer and metastasize (2) , which causes high mortality or severe impairment of quality of life, even if it is cured. The development of bladder tumors is thought to be a multifactorial process and to occur as a direct consequence of the mutagenic actions of chemical or physical carcinogens, such as tobacco smoking. The precise mechanisms underlying carcinogen-induced bladder carcinogenesis have not yet been clarified. To approach this question, N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced mouse bladder carcinoma model has been used widely since the 1970s. One feature of this mouse model is that BBN can induce high-grade non-muscle invasive bladder cancer, followed by muscle invasive bladder cancer, in almost all subject animals (3) .
In general, epithelial cells receive oncogenic growth signals that originate in the extracellular environment in response to carcinogenic stimuli (4) . Aberrant activation of mitogen-activated protein kinase (MAPK) cascades, such as c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK), and oncogenic signals involving AKT have been shown to lead to excessive cell growth and division in early-stage carcinogenesis (5) .
Specifically, up-regulation of oncogenic signaling genes involved in the Ras-Raf-MAPK cascade have been reported in the advanced stages of BBN-induced bladder cancer (6) . The MAPKs are activated by receptor signaling pathways, including receptor tyrosine kinases (such as epidermal growth factor receptor [EGFR] and type 1 insulin-like growth factor receptor [IGF-1R]). In addition, seven-transmembrane receptors (7TMRs) have been also reported to activate MAPK signaling. Among the 7TMRs leading to activation of MAPKs, chemokine receptor CXCR4, which is activated exclusively by its ligand stromal cell-derived factor 1 (SDF-1), is up-regulated in many kinds of cancers, including bladder carcinoma.
Indeed, CXCR4 was identified as the only chemokine receptor up-regulated in muscle-invasive bladder cancer by screening expression levels of all chemokine receptors in normal urothelium and bladder cancer. (7) . It is also up-regulated in high-grade non-muscle invasive bladder cancers including CIS (8) , although the role of SDF-1-CXCR4 signaling in bladder carcinogenesis remains unclear.
Thioredoxin interacting protein (TXNIP), also known as thioredoxin binding protein-2 (TBP-2) or vitamin D3 up-regulated protein 1 (VDUP1), is a multi-functional protein. It binds to and inhibits thioredoxin 1 (TRX1), a major redox-regulating molecule, and also plays roles in the development of NK cells, glucose metabolism, cell cycle arrest, and inflammatory 6 signal regulation (9) (10) (11) . Regarding the relationship between TXNIP and cancer, TXNIP expression is down-regulated in gastric, breast, and colorectal cancers (12) (13) (14) (15) . However, its expression level and role in bladder cancer have not been reported. Moreover, although several growth suppressive mechanisms of TXNIP have been extensively studied in vitro, the tumor suppressive functions have not been fully elucidated in vivo.
We previously analyzed comprehensive gene expression profiles in recurrent bladder cancer (16, 17) , and we have found that TXNIP is suppressed in bladder cancer. In the present study, we show that TXNIP is down-regulated according to grade and stage in human bladder cancers, and that deletion of Txnip accelerates BBN-induced bladder carcinogenesis in vivo.
Additionally, we show that restoration of TXNIP attenuates ERK activation upon SDF-1 stimulation. Furthermore, pharmacological blockade of SDF-1-CXCR4 signaling inhibits in vivo BBN-induced bladder carcinogenesis accompanied with marked down-regulation of ERK. Here, we show the significant role of TXNIP on SDF-1-CXCR4-ERK signaling pathway in the molecular mechanisms underlying carcinogen-induced bladder carcinogenesis.
Materials and methods

Quantitative RT-PCR
Total RNA was extracted using an RNeasy Mini kit (QIAGEN, Germany) from cultured cells or whole bladders and reverse-transcribed into cDNA using the First-Strand cDNA Synthesis Kit (GE Healthcare, Piscataway, NJ). Following primers were used in PCR reactions: human GAPDH (forward 5′-GAAGGTGAAGGTCGGAGTC-3′ and reverse 5′-GAAGATGGTGATGGGATTTC-3′), human TXNIP (forward 5′-ATGGTGATGTTCAAGAAGATCAAG-3′ and reverse 5′-CTCAGGGGCATACATAAAGA-3′), mouse Gapdh (forward 5′-ACCACAGTCCATGCCATCAC-3′ and reverse 5′-TCCACCACCCTGTTGCTGTA-3′), mouse Txnip (forward 5′-TCTCCTAGAAGAGCAGCCTACAGG-3′ and reverse 5′-CTCGAAGCCGAACTTGTACTCATA-3′). The real time PCR reaction was performed using the 7300 Real-Time PCR System and RT-PCR reagents (Power SYBR Green PCR Master Mix, Applied Biosystems, Tokyo, Japan) according to the manufacturer's protocol. The PCR reactions were done in triplicate; three independent experiments were performed using different sets of samples. Data were normalized relative to the expression level of GAPDH genes. Data in each group were compared with those in another group by post hoc test protected least significant difference (Fisher's PLSD); boxplot graphs were drawn using commercially available software.
Cell culture, stable transfectants, and stimulation by SDF-1α, EGF or IGF-1
Human bladder cancer cell lines: EJ, HT1376, J82, T24, KK47, RT112, RT4, 253J, and TCCSUP were used. The cells were cultured in RPMI 1640 media supplemented with 10% (100 ng/ml), EGF (50 ng/ml, eBioscience, San Diego, CA), or IGF-1 (250 ng/ml, Cell Sciences, Canton, MA). After 10 or 20 minutes, the cells were collected on ice and analyzed.
The timeframe analysis of pERK was performed using SDF-1α (100 ng/ml) in RPMI media without FBS.
Human bladder cancer specimens
Bladder cancer samples (n = 39) were taken by transurethral cold-cup biopsy under direct vision. Non-malignant ureteral urothelia were dissected and isolated by submucosal injection of normal saline from specimens of patients with kidney cancer (n = 6). Patients' characteristics including age, grade, sex, smoking habits, and recurrence-free survival are provided in Table 1 . Informed written consent was obtained from each patient before examination.
Txnip-deficient mouse and mouse bladder cancer model
The present animal experiment was approved by the Animal Research Committee of Kyoto University. Txnip hetero-knockout (+/-) mice were generated from C57B/6 mice and provided by the Institute for Viral Research, Kyoto University (19) . The mice were housed in a specific pathogen-free room. Six-to eight-week-old Txnip (-/-) knock-out (KO) mice and wild-type (+/+, WT) mice were given drinking water with or without 0.025% BBN (Tokyo Kasei Kogyo, Tokyo, Japan). In histopathological analysis, bladders were harvested at baseline and after 4, 8, 12, 16, 20, 
Western blot analysis
Total cellular proteins were extracted by disrupting the cells or homogenizing the whole bladders in RIPA buffer. Total cellular protein extracts from cultured cells, mouse bladder tissues, and human bladder urothelium were analyzed by SDS-PAGE. Proteins were transferred to a PVDF membrane, blocked with 1% non-fat dry milk, and incubated with antibodies for the following proteins: HA (Covance Japan, Tokyo, Japan), CXCR4, β-actin 10 (Abcam, Cambridge, UK), VDUP-1, SDF-1 (Santa Cruz, CA), AKT, phospho-AKT (pAKT, ser473), JNK, phospho-JNK (pJNK, Thr183/Tyr185), ERK, pERK (Cell Signaling Technology Japan, Tokyo, Japan). Stained bands were detected using an ECL-advanced system (GE Healthcare, UK) and a LAS 4000 Mini analyzer and ImageReader software (Fujifilm, Tokyo, Japan). Densitometric scans of the stained bands were performed with ImageJ software (http://rsbweb.nih.gov/ij/). Data were normalized relative to the baseline value in each group. The differences in densitometric values for pERK, pAKT, and pJNK between WT and Txnip-KO mice were determined by the Mann-Whitney U test.
Immunohistochemistry of mouse bladder cancer
After BBN treatment, mouse bladders were inflated and fixed in 10% formalin. Mice without BBN treatment were used as negative controls. Human bladder cancer specimens obtained by transurethral cold-cup biopsy were fixed in 10% formalin overnight. The tissues were embedded in paraffin and were stained with hematoxylin and eosin in accordance with standard procedures. The formalin-fixed and paraffin-embedded bladders were stained as described previously (8) with antibodies for VDUP1 (1:200 dilution) or pERK (1:100 dilution). The specificity of the staining was confirmed using the corresponding rabbit or mouse IgG as negative controls for primary antibodies. Each tissue sample was observed by an eclipse E1000 microscope (Nikon, Tokyo, Japan).
Treatment with CXCR4 antagonist TF14016
A potent CXCR4 antagonist, 4F-benzoyl-TN14003 (TF14016), was synthesized as described previously (20) . TF14016 was dissolved with sterile water. TF14016 (7.5 mg/kg) was injected subcutaneously into nine each wild-type and Txnip-KO mice, every other day, in conjunction with 0.025% BBN administration. After 12 weeks of BBN administration, bladders were harvested 30 minutes after injection of TF14016 and analyzed using immunohistochemistry or western blot analysis. Figure 1C ). Interestingly, a 37% decrease in Txnip expression was observed at 4 weeks of BBN administration, at which no malignant changes were identified histologically. These data indicated that the expression of TXNIP gene was suppressed in the course of human and mouse bladder carcinogenesis.
Results
Txnip expression is down-regulated in human bladder cancers and in the BBN
Knock-out of Txnip accelerates BBN-induced bladder carcinogenesis
To determine whether the decreased expression of Txnip contributes to the development of bladder cancer, the prevalence of bladder cancer in Txnip-KO mice was compared with that in WT mice, using the BBN-induced bladder carcinogenesis model. Bladder cancer was pathologically identified in 60% (3 out of 5) and 100% (7 out of 7) of the Txnip-KO mice at 4 and 8 weeks of BBN administration, respectively, whereas it was identified in none of 5 and only 22% (2 out of 9) of the WT mice at 4 and 8 weeks, respectively (Figures 2A and B ).
When focusing on high-grade CIS, Txnip-KO mice developed this type of bladder cancers about 4 weeks earlier than WT mice ( Figure 2C ). Moreover, invasive bladder cancer (pT1 or more) and/or squamous cell carcinoma (SCC), which have characteristic histological features to advanced BBN-induced mouse bladder cancers, were observed also about 4 weeks earlier in the Txnip-KO mice than in the WT mice ( Figure 2D ). Thus, knocking-out Txnip accelerated BBN-induced bladder carcinogenesis, suggesting that TXNIP plays a suppressive role for bladder carcinogenesis. Although bladder carcinogenesis in WT mice is delayed, it is not prevented and is similar to the carcinogenesis in WT mice at 16-20 weeks of BBN treatment. This is likely because by that time TXNIP levels were similar in the two groups as shown in Figure 2E . TXNIP level in bladder urothelium was down-regulated at 12 and 20 weeks of BBN treatment compared to baseline in WT mice (n=3 in each group, Figures 2E) .
Phosphorylation of ERK is enhanced in Txnip-KO mouse bladders during BBN-induced bladder carcinogenesis
To investigate the molecular mechanisms underlying bladder carcinogenesis in Txnip-KO (Figures 4A, B , and S1). On the other hand, there were no differences in pERK upon EGF or IGF-1 stimulation between 253J-HA-TXNIP-2 and control cells ( Figure 4C) . Similar results were observed in the other two stable transfectants (253J-HA-TXNIP-1 and TCCSUP-HA-TXNIP) upon EGF or IGF-1 stimulation (data not shown). There were also no differences in the expression levels of corresponding receptors, including EGFR, IGFR, CXCR4, phospho-EGFR, or phospho-IGF-1R (data not shown).
These results indicate that overexpression of TXNIP attenuates SDF-1-CXCR4-induced activation of ERK exclusively.
CXCR4 antagonist TF14016 suppresses pERK and BBN-induced carcinogenesis in
Txnip-KO mice
The expression status of SDF-1, CXCR4, ERK and pERK were assessed in BBN-induced bladder carcinogenesis. SDF-1 and ERK were constantly expressed until 8 weeks of BBN administration, whereas CXCR4 was gradually up-regulated in the course of bladder carcinogenesis in the WT mice. When Txnip-KO mice were compared with WT mice, there were no obvious differences in the expression of SDF-1 and CXCR4. On the other hand, the expression of pERK was more enhanced in Txnip-KO mice than in the WT mice ( Figure 5A ).
To assess the impact of activation of ERK induced by SDF-1-CXCR4 stimulation on enhancement of bladder carcinogenesis in Txnip-KO mice, SDF-1-CXCR4 signaling was blocked by a specific CXCR4 antagonist TF14016 in both WT mice and Txnip-KO mice.
TF14016 was injected subcutaneously into WT mice and Txnip-KO mice every other day for 12 weeks during BBN administration. No significant adverse effects, including weight loss, were observed due to TF14016. Western blot analysis demonstrated that TF14016 markedly attenuated pERK in the mouse bladder of both groups to the similar level after 12 weeks of BBN consumption ( Figure 5B ). Pathological examination revealed that the prevalence of malignant bladder lesion was remarkably lower in TF14016-treated WT mice and Txnip-KO mice than in each control mice ( Figures 5C and D) .
Discussion
The present study shows novel findings that expression of Txnip mRNA is suppressed in human bladder cancers and in a mouse model of BBN-induced bladder carcinogenesis.
Moreover, we have clearly demonstrated that loss of Txnip facilitates BBN-induced mouse bladder carcinogenesis using Txnip-KO mice ( Figure 6 ). In general, a tumor suppressor gene is defined as a gene whose partial or complete inactivation leads to an increased likelihood of cancer development (4) . Txnip is thought to be a tumor suppressor gene based on observational evidence of suppressed expression in cancer tissues from various origins (12) (13) (14) (15) and functional verification using cultured cancer cells in in vitro experimental series (9) (10) (11) .
Reportedly, Txnip-deficient mice are also predisposed to renal (21) and hepatocellular (22, 23) carcinomas. Our data, which indicates that TXNIP functions as a tumor suppressor in urothelium, is consistent with its decreased expression in several kinds of cancers.
We have investigated in vivo functional consequences of TXNIP loss using a BBN-induced bladder carcinogenesis model in the Txnip-KO mice. In general, carcinogenic stimuli, such as BBN, boost oncogenic growth-stimulatory signals, leading to excessive cell growth and division at the early stage of carcinogenesis (5) . Therefore, we investigated ERK, JNK and AKT signaling as major growth-stimulatory signals, and found that ERK was more active in Txnip-KO mice than in WT mice. Aberrant activation of ERK, a second messenger involved in an important oncogenic signal transduction pathway, is reportedly associated with bladder carcinogenesis, among other cancers. On the other hand, some possible mechanisms of TXNIP have been listed in tumor suppression. A previous in vitro study reported that TXNIP decreases cell proliferation by restricting cell cycle progression; TXNIP deficiency reduced expression of p27, a cyclin-dependent kinase inhibitor (24) . Alteration of redox status has been also proposed as a mechanism of tumor suppression, since TXNIP inhibit the activity of TRX1. However, under the conditions we used to induce bladder carcinogenesis, we could not find obvious differences in the expression of TRX1, cell-cycle related genes including p27, and the status of redox (8-hydroxy-2′-deoxyguanosine 
) between
Txnip-KO mice and WT mice (data not shown). Collectively, TXNIP can function as a tumor suppressor mainly through regulating ERK activity, which is strongly associated with oncogenic process toward bladder carcinogenesis. Since the present study remains observational, the precise mechanism of action should be clarified in the next studies.
Phosphorylation of ERK can occur via activation of either of several signal pathways including receptor tyrosine kinases (i.e., IGF-1R and EGFR) or 7TMRs (i.e., CXCR4). In the present study, BBN administration induced both CXCR4 expression in urothelial cells and SDF-1 expression in stromal mesenchyme cells. In contrast, bladder cancer cell lines transfected with TXNIP demonstrated attenuated CXCR4-ERK activation upon SDF-1 stimuli.
Therefore, CXCR4 is considered to be a major up-stream receptor activating ERK signaling;
it plays an important role in bladder carcinogenesis by stimulating several transcription factors. Indeed, CXCR4 antagonist significantly attenuates ERK activation and suppresses bladder carcinogenesis in both WT and Txnip-KO mouse model, to almost the same level.
Since the effects of TXNIP deletion is abrogated by CXCR4 antagonist, there seems to be a causal link between TXNIP deletion and enhanced bladder carcinogenesis. These results suggest that TXNIP suppression facilitates bladder carcinogenesis by enhancing CXCR4-ERK activation.
Another important upstream regulator of ERK is the Ras signaling pathway, which is activated by receptor tyrosine kinases such as IGF-1R, EGFR and FGFR3. Aberrant activation of Ras oncoproteins is associated with development of low-grade non-muscle invasive bladder cancer (25) . However, BBN-induced mouse bladder cancer shows a morphologic effect similar to another bladder carcinogenesis pathway, namely high-grade CIS muscle-invasive cancer pathway (25) . In the present study, restoration of TXNIP did not alter ERK activation upon IGF-1 or EGF stimuli; and CXCR4 blockade suppressed BBN-induced carcinogenesis. Also, TXNIP expression is significantly more suppressed in high-grade muscle-invasive human bladder cancers than in low-grade non-muscle-invasive types of cancer. These findings suggest that activation of SDF-1-CXCR4 signaling drives a CIS muscle-invasive bladder cancer pathway, and that a major effect of TXNIP loss is to facilitate this pathway. Recent reports support the notion that the ERK pathway plays an important role in muscle invasive bladder cancer (26) (27) (28) (29) . Because TXNIP expression is also suppressed in low-grade non-muscle-invasive bladder cancers compared to normal urothelia, loss of TXNIP may play other roles in bladder carcinogenesis, which should be elucidated in future studies.
Using a BBN-induced bladder carcinogenesis mouse model, we have shown that CXCR4 antagonist TF14016 can reduce bladder carcinogenesis. The 14-mer peptide T140 was developed from structure-activity relationship studies of two antibacterial and antiviral peptides; 17-mer peptide tachyplesins and 18-mer peptide polyphemusins isolated from the Japanese horseshoe crab (Tachypleus tridentatus) and the American horseshoe crab (Limulus polyphemus), respectively. T140 possesses potent anti-HIV activity by binding specifically to CXCR4 and TF14016 is a potent and bio-stable T140 analog (20) . To our knowledge, this is the first report of successful bladder cancer prevention using a drug that attenuates a specific oncogenic signal. A limitation of the present study is that the therapeutic effect of TF14016 on established bladder tumors have not been clarified. Therefore, it seems the most reasonable and practical to use this drug to prevent recurrence of high-grade bladder cancer after transurethral resection (TUR). Prevention of post-TUR bladder cancer recurrence is a major clinical challenge, although some anti-cancer drugs and Bacillus Calmette-Guérin (BCG) are currently available with partial effects. Although some newly developed antigen-based drugs and molecular-targeted agents have been tested for this purpose (30) , none of these novel treatments has been established so far. Peptide-based TF14016 and its analogs also offer advantages in terms of cost over other novel treatment modalities. Although we did not find 20 any lethal reaction or significant weight loss during the 12 weeks' treatment, further evaluation of acute and chronic adverse events is essential for the future clinical use.
In conclusion, TXNIP, which is silenced during bladder carcinogenesis, suppresses ERK activation in the SDF-1-CXCR4 signaling and also bladder carcinogenesis, suggesting that SDF-1-CXCR4-ERK signaling might be a good target to prevent bladder cancer.
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Figure legends
Human high grade and muscle-invasive bladder cancers (arrows). 
